Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021
HomeNON PROFITStudy Highlights Potential for Low-Intensity Surveillance As Option for Some Patients with Non-Muscle Invasive Bladder Cancer

Study Highlights Potential for Low-Intensity Surveillance As Option for Some Patients with Non-Muscle Invasive Bladder Cancer

Low-intensity cystoscopic surveillance may be a viable option for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), according to a new abstract from researchers in New Hampshire. This abstract will be presented to the media during a special session moderated by AUA Public Media Chair Sam Chang on May 15 at 8:30 a.m.

In this retrospective cohort study of 1,542 veterans diagnosed with high-risk NMIBC between 2005 and 2011 with follow up care through 2014, researchers at Dartmouth-Hitchcock reviewed the association of low-intensity surveillance cystoscopies (one to five procedures) vs. high-intensity cystoscopies (six or more procedures) with frequency of transurethral resections, as well as risk of progression and bladder cancer death in patients.

Patients who underwent low-intensity surveillance (520, or 33.7 percent) were found to have fewer transurethral resections than those with high-intensity surveillance (37 vs. 99 per 100 person-years). Stage of disease (non-invasive vs. invasive) was not found to be a confounding factor; no statistical difference was found between frequency or cystoscopic surveillance and risk of bladder cancer progression or death. Patients undergoing low-intensity surveillance had a decreased risk of progression to invasive disease or death compared to the high-intensity group (19.3 percent vs. 31.4 percent at five years). Similarly, of the patients with non-invasive disease who underwent fewer cystoscopies. 5.7 percent had an increased risk of death at five years compared to 8.2 percent of patients with more aggressive surveillance protocols.

“The authors should be commended for their efforts to determine the most appropriate surveillance schedule for patients with non-muscle invasive bladder cancer. The findings are provocative, but every retrospective study is affected by selection bias,” Dr. Chang said. “I want to caution, as the authors themselves conclude, that their findings serve to justify a future clinical trial and should NOT guide current clinical practice.”


The Impact of Low- versus High-Intensity Surveillance Cystoscopy on Surgical Care and Cancer Outcomes in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Michael Rezaee, Kristine Lynch, Zhongze Li, Todd MacKenzie, John Seigne, Douglas Robertson, Brenda Sirovich, Philip Goodney, Florian Schroeck

Introduction: Surveillance guidelines for NMIBC are based on expert opinion and informed by limited evidence. To assess the association of low- vs. guideline-recommended high-intensity cystoscopic surveillance with outcomes among patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Methods: A retrospective cohort study of Veterans Affairs patients diagnosed with high-risk NMIBC between 2005 and 2011 with follow-up through 2014. Patients were categorized by number of surveillance cystoscopies over two years following diagnosis: low- (1-5) vs. high-intensity (6 or more) surveillance. Propensity score adjusted regression models were used to assess the association of low-intensity cystoscopic surveillance with frequency of transurethral resections, and risk of progression to invasive disease and bladder cancer death.

Results: Among 1,542 patients, 520 (33.7%) underwent low-intensity cystoscopic surveillance. Patients undergoing low-intensity surveillance had fewer transurethral resections (37 vs. 99 per 100 person-years; p<0.001). Low vs. high-intensity surveillance was not associated with risk of bladder cancer death among patients with non-invasive (cumulative incidence [CIn] 5.7% vs. 8.2% at 5 years, p=0.25) or with invasive disease at diagnosis (CIn 10.1% vs. 9.7% at 5 years, p=0.81). Among a subset of patients with non-invasive disease, low-intensity surveillance was associated with decreased risk of progression to invasive disease or bladder cancer death (CIn 19.3% vs. 31.4% at 5 years, p=0.002).

Conclusions: Patients with high-risk NMIBC undergoing low- vs. high-intensity cystoscopic surveillance underwent fewer transurethral resections, but did not experience an increased risk of progression or bladder cancer death. These findings provide a strong rationale for a clinical trial to determine whether low-intensity surveillance is comparable to high-intensity surveillance for cancer control in high-risk NMIBC.

Funding Source: None

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy